Sponsor: 
Merck Sharp & Dohme (Australia)
Administration route: 
Intramuscular injection, Subcutaneous injection
Vaccine group: 
Combination vaccines

Registered for use in people aged ≥12 months.

MMR — measles-mumps-rubella combination vaccine

Lyophilised pellet in a monodose vial with separate diluent.

Each 0.5 mL reconstituted dose contains:

  • ≥1000 tissue culture infectious dose 50% (TCID50) of live attenuated measles virus (Enders’ attenuated Edmonston strain)
  • ≥12,500 TCID50 of live attenuated mumps virus (Jeryl Lynn B level strain)
  • ≥1000 TCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
  • 14.5 mg sorbitol
  • 1.9 mg sucrose
  • 14.5 mg hydrolysed porcine gelatin
  • ≤0.3 mg recombinant human albumin
  • <1 ppm fetal bovine serum
  • 25 µg neomycin

For full details, refer to the product information and consumer medicine information sheets for M-M-R II vaccine available on the TGA website.

Page history

Last updated: 
23 April 2019
Last reviewed: 
23 April 2019

Definitions

MMR
measles-mumps-rubella